U.S. Patent Application Allowed For Cancer Drug
2/20/03
Mr. Doug Bachman, Vice President of Corporate Development of Altachem Pharma Ltd. is pleased to announce that Altachem's U.S. Patent Application, titled 'Perylenequinones for use as photosensitizers and sonosensitizers'has been allowed for its proprietary drug for cancer treatment.
'This patent recognizes and provides support for Altachem's integrated approach for the treatment of cancer using sonodynamic therapy,'states Mr. Bachman. Mr. Bachman also states, 'HB derivatives have been demonstrated to kill cancer cells and tumors upon activation by red, visible light and/or ultrasound. The combination of these two activation modalities offers great flexibility and disease inclusion, since photodynamic therapy is useful for surface lesions, while sonodynamic therapy is appropriate for the tumor masses deep in the body.'
Altachem's technology platform is based on a unique non-toxic family of compounds. The active ingredient is a derivative of a small molecular weight compound called HB, isolated from perylenequinone pigments from a fungal parasite of bamboo.
Altachem Pharma Ltd. is a publicly traded (TSX Venture Exchange: AAF), Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. The Corporation is developing a multi-tiered, integrated approach for the treatment of HIV/AIDS and cancer using non-toxic therapeutic products and adjunct therapies. The lead products of the Corporation are based on its two proprietary drugs: ACP-HIP and HB. The Corporation's manufacturing facilities located in Edmonton, Alberta and Shanghai, China are certified compliant with internationally recognized quality systems standards.
Certain information contained in this press release may be forward-looking and is subject to unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable.
CONTACT: TEL: (780) 486-8331 x 331 Roger Andrews, I.R., Altachem
Toll Free: 1-877-502-5939
FAX: (780) 448-1436
Email: roger@altachempharma.com
Website: www.altachempharma.com
TEL: (514) 939-3989 Barry Mire, Renmark Financial Communications
FAX: (514) 939-3717
Email: bmire@renmarkfinancial.com
Website: www.renmarkfinancial.com |
